SLC37A2 is an endoplasmic reticulum-resident phosphate/glucose-6-phosphate antiporter that catalyzes the bidirectional exchange of glucose-6-phosphate and inorganic phosphate across the ER membrane 1. Unlike SLC37A4 (G6PT), SLC37A2 cannot functionally couple with glucose-6-phosphatase enzymes and does not participate in blood glucose homeostasis 2. Instead, SLC37A2 appears to function in metabolic reprogramming and cellular adaptation. In glioblastoma, SLC37A2 expression is upregulated under hypoxic stress in a HIF-1α-dependent manner and associates with cancer stem cell phenotypes and neurosphere formation 3. In breast cancer, SLC37A2 mediates metabolic reprogramming through the RAB10/mTOR pathway, regulating autophagy and ferroptosis 4. In inflammatory bowel disease, SLC37A2 functions as a downstream target of m6A modification, promoting M2-type macrophage polarization via the METTL3-SLC37A2-YTHDF1 axis 5. SLC37A2 also associates with gastric cancer progression and cachexia-related immune dysregulation 6. While SLC37A2's precise physiological role remains incompletely characterized, its involvement in metabolic adaptation, immune regulation, and cancer progression suggests therapeutic potential in these disease contexts.